The DOI matches its Crossref record; 179 of the 179 references it cites were found in a registry or an index.
Human papillomavirus vaccine against cervical cancer: Opportunity and challenge
Open accessAbstract
Cervical cancer is one of the most common cancers threatening women's health, and the persistent infection of high-risk human papillomavirus (HPV) is closely related to the pathogenesis of cervical cancer and many other cancers. The carcinogenesis is a complex process from precancerous lesion to cancer, which provides an excellent window for clinical prevention, diagnosis, and treatment. However, despite the various preventions and treatments such as HPV screening, prophylactic HPV vaccines, surgery, radiotherapy, and chemotherapy, the disease burden remains heavy worldwide. Currently, three types of prophylactic vaccines, quadrivalent HPV vaccine, bivalent HPV vaccine, and a new nonavalent HPV vaccine, are commercially available. Although these vaccines are effective in protecting against 90% of HPV infection, they provide limited benefits to eliminate pre-existing infections. Therefore, new progress has been made in the development of therapeutic vaccines. Therapeutic vaccines differ from prophylactic vaccines in that they aim to stimulate cell-mediated immunity and kill the infected cells rather than neutralizing antibodies. This review aims at systematically covering the progress, current status and future prospects of various vaccines in development for the prevention and treatment of HPV-associated lesions and cancers and laying foundations for the development of the new original vaccine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic cells and the control of immunity
Banchereau, J., & Steinman, R. M. (1998) · Nature · doi:10.1038/32588 · Cited by 14,336
Papillomaviruses and cancer: from basic studies to clinical application
zur Hausen, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc798 · Cited by 4,024
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S., & Reis e Sousa, C. (2004) · Science · doi:10.1126/science.1093616 · Cited by 3,444
de Sanjose, S., Quint, W. G., Alemany, L., Geraets, D. T., Klaustermeier, J. E., Lloveras, B., Tous, S., Felix, A., Bravo, L. E., Shin, H.-R., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70230-8 · Cited by 2,728
Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
Human papillomavirus and cervical cancer
Burd, E. M. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.1.1-17.2003 · Cited by 2,420
Dürst, M., Gissmann, L., Ikenberg, H., & zur Hausen, H. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.12.3812 · Cited by 2,025
Ronco, G., Dillner, J., Elfström, K. M., Tunesi, S., Snijders, P. J. F., Arbyn, M., Kitchener, H., Segnan, N., Gilham, C., Giorgi-Rossi, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62218-7 · Cited by 1,810
Human papillomavirus oncoproteins: pathways to transformation
Moody, C. A., & Laimins, L. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2886 · Cited by 1,751
Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments
Bernard, H.-U., Burk, R. D., Chen, Z., van Doorslaer, K., Hausen, H. Z., & de Villiers, E.-M. (2010) · Virology · doi:10.1016/j.virol.2010.02.002 · Cited by 1,669
Paavonen, J., Naud, P., Salmerón, J., Wheeler, C., Chow, S.-N., Apter, D., Kitchener, H., Castellsague, X., Teixeira, J., Skinner, Sr., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61248-4 · Cited by 1,655
Global burden of cancers attributable to infections in 2012: a synthetic analysis
Plummer, M., de Martel, C., Vignat, J., Ferlay, J., Bray, F., & Franceschi, S. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(16)30143-7 · Cited by 1,635
Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis
Clifford, G. M., Smith, J. S., Plummer, M., Muñoz, N., & Franceschi, S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600688 · Cited by 1,561
Structure and transcription of human papillomavirus sequences in cervical carcinoma cells
Schwarz, E., Freese, U. K., Gissmann, L., Mayer, W., Roggenbuck, B., Stremlau, A., & Hausen, H. Z. (1985) · Nature · doi:10.1038/314111a0 · Cited by 1,483
Integrated genomic and molecular characterization of cervical cancer
The Cancer Genome Atlas Research Network (2017) · Nature · doi:10.1038/nature21386 · Cited by 1,479
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women
Joura, E. A., Giuliano, A. R., Iversen, O.-E., Bouchard, C., Mao, C., Mehlsen, J., Moreira, E. D., Ngan, Y., Petersen, L. K., Lazcano-Ponce, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405044 · Cited by 1,433
Chapter 2: The burden of HPV-related cancers
Parkin, D. M., & Bray, F. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.111 · Cited by 1,385
Boshart, M., Gissmann, L., Ikenberg, H., Kleinheinz, A., Scheurlen, W., & zur Hausen, H. (1984) · The EMBO Journal · doi:10.1002/j.1460-2075.1984.tb01944.x · Cited by 1,305
Decisions About Dendritic Cells: Past, Present, and Future
Steinman, R. M. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-100311-102839 · Cited by 1,274
Human papillomavirus and cervical cancer
Crosbie, E. J., Einstein, M. H., Franceschi, S., & Kitchener, H. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60022-7 · Cited by 1,171
Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., & Schiller, J. T. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.24.12180 · Cited by 1,110
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Lowik, M. J. G., Berends-van der Meer, D. M. A., Vloon, A. P. G., Essahsah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810097 · Cited by 1,102
Bruni, L., Diaz, M., Barrionuevo-Rosas, L., Herrero, R., Bray, F., Bosch, F. X., de Sanjosé, S., & Castellsagué, X. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(16)30099-7 · Cited by 824
Trimble, C. L., Morrow, M. P., Kraynyak, K. A., Shen, X., Dallas, M., Yan, J., Edwards, L., Parker, R. L., Denny, L., Giffear, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00239-1 · Cited by 727
Lehtinen, M., Paavonen, J., Wheeler, C. M., Jaisamrarn, U., Garland, S. M., Castellsagué, X., Skinner, S. R., Apter, D., Naud, P., Salmerón, J., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70286-8 · Cited by 704
Stevanović, S., Draper, L. M., Langhan, M. M., Campbell, T. E., Kwong, M. L., Wunderlich, J. R., Dudley, M. E., Yang, J. C., Sherry, R. M., Kammula, U. S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.9093 · Cited by 682
Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.
Yee, C., Krishnan-Hewlett, I., Baker, C. C., Schlegel, R., & Howley, P. M. (1985) · PubMed · Cited by 677
Hildesheim, A., Herrero, R., Wacholder, S., Rodriguez, A. C., Solomon, D., Bratti, M. C., Schiller, J. T., Gonzalez, P., Dubin, G., Porras, C., et al. (2007) · JAMA · doi:10.1001/jama.298.7.743 · Cited by 666
Cantelmo, A. R., Conradi, L.-C., Brajic, A., Goveia, J., Kalucka, J., Pircher, A., Chaturvedi, P., Hol, J., Thienpont, B., Teuwen, L.-A., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.006 · Cited by 659
Harro, C. D., Pang, Y.-Y. S., Roden, R. B. S., Hildesheim, A., Wang, Z., Reynolds, M. J., Mast, T. C., Robinson, R., Murphy, B. R., Karron, R. A., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.284 · Cited by 607
Biological activities and molecular targets of the human papillomavirus E7 oncoprotein
Münger, K., Basile, J. R., Duensing, S., Eichten, A., Gonzalez, S. L., Grace, M., & Zacny, V. L. (2001) · Oncogene · doi:10.1038/sj.onc.1204860 · Cited by 588
Kjaer, S. K., Frederiksen, K., Munk, C., & Iftner, T. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq356 · Cited by 579
Cross-roads in the classification of papillomaviruses
de Villiers, E.-M. (2013) · Virology · doi:10.1016/j.virol.2013.04.023 · Cited by 540
Narisawa‐Saito, M., & Kiyono, T. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00546.x · Cited by 528
Jeon, S., & Lambert, P. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1654 · Cited by 527
Wheeler, C. M., Castellsagué, X., Garland, S. M., Szarewski, A., Paavonen, J., Naud, P., Salmerón, J., Chow, S.-N., Apter, D., Kitchener, H., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70287-x · Cited by 507
Zhou, J., Sun, X. Y., Stenzel, D. J., & Frazer, I. H. (1991) · Virology · doi:10.1016/0042-6822(91)90772-4 · Cited by 506
Garland, S. M., Kjaer, S. K., Muñoz, N., Block, S. L., Brown, D. R., DiNubile, M. J., Lindsay, B. R., Kuter, B. J., Perez, G., Dominiak-Felden, G., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw354 · Cited by 497
Huh, W. K., Joura, E. A., Giuliano, A. R., Iversen, O.-E., de Andrade, R. P., Ault, K. A., Bartholomew, D., Cestero, R. M., Fedrizzi, E. N., Hirschberg, A. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31821-4 · Cited by 465
Condylomata acuminata and human genital cancer.
Hausen, H. Z. (1976) · PubMed · Cited by 446
Malagón, T., Drolet, M., Boily, M.-C., Franco, E. L., Jit, M., Brisson, J., & Brisson, M. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70187-1 · Cited by 429
HPV vaccines – A review of the first decade
Harper, D. M., & DeMars, L. R. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.04.004 · Cited by 429
Condylomatous lesions of the cervix and vagina. I. Cytologic patterns.
Meisels, A., & Fortin, R. (1977) · PubMed · Cited by 422
Delany, I., Rappuoli, R., & De Gregorio, E. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201403876 · Cited by 420
Dobson, S. R. M., McNeil, S., Dionne, M., Dawar, M., Ogilvie, G., Krajden, M., Sauvageau, C., Scheifele, D. W., Kollmann, T. R., Halperin, S. A., et al. (2013) · JAMA · doi:10.1001/jama.2013.1625 · Cited by 417
Updating the Natural History of Human Papillomavirus and Anogenital Cancers
Moscicki, A.-B., Schiffman, M., Burchell, A., Albero, G., Giuliano, A. R., Goodman, M. T., Kjaer, S. K., & Palefsky, J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.05.089 · Cited by 413
The human papillomavirus family and its role in carcinogenesis
Tommasino, M. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.11.002 · Cited by 411
The known unknowns of HPV natural history
Gravitt, P. E. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57149 · Cited by 378
Richards, R. M., Lowy, D. R., Schiller, J. T., & Day, P. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508815103 · Cited by 375
HUMAN PAPILLOMAVIRUS INFECTIONS IN WOMEN WITH AND WITHOUT ABNORMAL CERVICAL CYTOLOGY
Villiers, E.-M. D., Schneider, A., Miklaw, H., Papendick, U., Wagner, D., Wesch, H., Wahrendorf, J., & Hausen, H. Z. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91072-5 · Cited by 371
Beyond Cervical Cancer: Burden of Other HPV-Related Cancers Among Men and Women
Chaturvedi, A. K. (2010) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2010.01.016 · Cited by 361
Listeriolysin O: a phagosome-specific lysin
Schnupf, P., & Portnoy, D. A. (2007) · Microbes and Infection · doi:10.1016/j.micinf.2007.05.005 · Cited by 360
Pastrana, D. V., Buck, C. B., Pang, Y.-Y. S., Thompson, C. D., Castle, P. E., FitzGerald, P. C., Krüger Kjaer, S., Lowy, D. R., & Schiller, J. T. (2004) · Virology · doi:10.1016/j.virol.2003.12.027 · Cited by 357
Human papillomavirus vaccines: WHO position paper
WHO (2009) · Biologicals · doi:10.1016/j.biologicals.2009.04.005 · Cited by 357
Human papillomavirus vaccines: WHO position paper, May 2017–Recommendations
(2017) · Vaccine · doi:10.1016/j.vaccine.2017.05.069 · Cited by 352
Arrangement of L2 within the Papillomavirus Capsid
Buck, C. B., Cheng, N., Thompson, C. D., Lowy, D. R., Steven, A. C., Schiller, J. T., & Trus, B. L. (2008) · Journal of Virology · doi:10.1128/jvi.02726-07 · Cited by 349
Triage of HPV positive women in cervical cancer screening
Wentzensen, N., Schiffman, M., Palmer, T., & Arbyn, M. (2016) · Journal of Clinical Virology · doi:10.1016/j.jcv.2015.11.015 · Cited by 347
Current understanding of the mechanism of HPV infection
Schiller, J. T., Day, P. M., & Kines, R. C. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.04.004 · Cited by 332
Maciag, P. C., Radulovic, S., & Rothman, J. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.041 · Cited by 324
Kreimer, A. R., Rodriguez, A. C., Hildesheim, A., Herrero, R., Porras, C., Schiffman, M., González, P., Solomon, D., Jiménez, S., Schiller, J. T., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr319 · Cited by 324
Modified Vaccinia Virus Ankara
Volz, A., & Sutter, G. (2017) · Advances in Virus Research · doi:10.1016/bs.aivir.2016.07.001 · Cited by 323
Dyson, N., Guida, P., Münger, K., & Harlow, E. (1992) · Journal of Virology · doi:10.1128/jvi.66.12.6893-6902.1992 · Cited by 314
de Jong, A., van Poelgeest, M. I. E., van der Hulst, J. M., Drijfhout, J. W., Fleuren, G. J., Melief, C. J. M., Kenter, G., Offringa, R., & van der Burg, S. H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0831 · Cited by 309
Kreimer, A. R., Struyf, F., Del Rosario-Raymundo, M. R., Hildesheim, A., Skinner, S. R., Wacholder, S., Garland, S. M., Herrero, R., David, M.-P., & Wheeler, C. M. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00047-9 · Cited by 306
DNA vaccine for cancer immunotherapy
Yang, B., Jeang, J., Yang, A., Wu, T. C., & Hung, C.-F. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/21645515.2014.980686 · Cited by 276
Opalka, D., Lachman, C. E., MacMullen, S. A., Jansen, K. U., Smith, J. F., Chirmule, N., & Esser, M. T. (2003) · Clinical and Vaccine Immunology · doi:10.1128/cdli.10.1.108-115.2003 · Cited by 276
Doran, S. L., Stevanović, S., Adhikary, S., Gartner, J. J., Jia, L., Kwong, M. L. M., Faquin, W. C., Hewitt, S. M., Sherry, R. M., Yang, J. C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02424 · Cited by 272
Hausen, H. Z., Meinhof, W., Scheiber, W., & Bornkamm, G. W. (1974) · International Journal of Cancer · doi:10.1002/ijc.2910130509 · Cited by 271
L2, the minor capsid protein of papillomavirus
Wang, J. W., & Roden, R. B. S. (2013) · Virology · doi:10.1016/j.virol.2013.04.017 · Cited by 266
Are 20 human papillomavirus types causing cervical cancer?
Arbyn, M., Tommasino, M., Depuydt, C., & Dillner, J. (2014) · The Journal of Pathology · doi:10.1002/path.4424 · Cited by 264
Watts, C. (2004) · Nature Immunology · doi:10.1038/ni1088 · Cited by 259
Kim, T. J., Jin, H.-T., Hur, S.-Y., Yang, H. G., Seo, Y. B., Hong, S. R., Lee, C.-W., Kim, S., Woo, J.-W., Park, K. S., et al. (2014) · Nature Communications · doi:10.1038/ncomms6317 · Cited by 259
Daayana, S., Elkord, E., Winters, U., Pawlita, M., Roden, R., Stern, P. L., & Kitchener, H. C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605611 · Cited by 252
Naud, P. S., Roteli-Martins, C. M., De Carvalho, N. S., Teixeira, J. C., de Borba, P. C., Sanchez, N., Zahaf, T., Catteau, G., Geeraerts, B., & Descamps, D. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.29532 · Cited by 251
Day, P. M., Baker, C. C., Lowy, D. R., & Schiller, J. T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404229101 · Cited by 245
Sankaranarayanan, R., Prabhu, P. R., Pawlita, M., Gheit, T., Bhatla, N., Muwonge, R., Nene, B. M., Esmy, P. O., Joshi, S., Poli, U. R. R., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00414-3 · Cited by 242
Human Papillomavirus, Human Immunodeficiency Virus and Immunosuppression
Denny, L. A., Franceschi, S., de Sanjosé, S., Heard, I., Moscicki, A. B., & Palefsky, J. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.06.045 · Cited by 237
Use of live bacterial vaccine vectors for antigen delivery: potential and limitations
Medina, E., & Guzmán, C. A. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00354-6 · Cited by 234
ICTV Virus Taxonomy Profile: Papillomaviridae
Van Doorslaer, K., Chen, Z., Bernard, H.-U., Chan, P. K. S., DeSalle, R., Dillner, J., Forslund, O., Haga, T., McBride, A. A., Villa, L. L., et al. (2018) · Journal of General Virology · doi:10.1099/jgv.0.001105 · Cited by 228
Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV e6‐e7 anti‐sense RNA
von Knebel Doeberitz, M., Rittmüller, C., Hausen, H. Z., & dürst, M. (1992) · International Journal of Cancer · doi:10.1002/ijc.2910510527 · Cited by 223
Present status of human papillomavirus vaccine development and implementation
Herrero, R., González, P., & Markowitz, L. E. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70481-4 · Cited by 215
van Poelgeest, M. I. E., Welters, M. J. P., van Esch, E. M. G., Stynenbosch, L. F. M., Kerpershoek, G., van Persijn van Meerten, E. L., van den Hende, M., Löwik, M. J. G., Berends-van der Meer, D. M. A., Fathers, L. M., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-88 · Cited by 193
Wheeler, C. M., Skinner, S. R., Del Rosario-Raymundo, M. R., Garland, S. M., Chatterjee, A., Lazcano-Ponce, E., Salmerón, J., McNeil, S., Stapleton, J. T., Bouchard, C., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)30120-7 · Cited by 191
CONDYLOMATOUS LESIONS OF THE CERVIX AND VAGINA. I. CYTOLOGIC PATTERNS
MEISELS, A., & FORTIN, R. (1977) · OBSTETRICAL & GYNECOLOGICAL SURVEY · doi:10.1097/00006254-197705000-00023 · Cited by 190
Viral vectors as vaccine platforms: from immunogenicity to impact
Ewer, K. J., Lambe, T., Rollier, C. S., Spencer, A. J., Hill, A. V., & Dorrell, L. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.014 · Cited by 187
Genome-wide siRNA screen identifies the retromer as a cellular entry factor for human papillomavirus
Lipovsky, A., Popa, A., Pimienta, G., Wyler, M., Bhan, A., Kuruvilla, L., Guie, M.-A., Poffenberger, A. C., Nelson, C. D. S., Atwood, W. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1302164110 · Cited by 186
Skinner, S. R., Szarewski, A., Romanowski, B., Garland, S. M., Lazcano-Ponce, E., Salmerón, J., Del Rosario-Raymundo, M. R., Verheijen, R. H. M., Quek, S. C., da Silva, D. P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60920-x · Cited by 184
Human Papillomavirus Laboratory Testing: the Changing Paradigm
Burd, E. M. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-15 · Cited by 176
Hopman, A. H., Smedts, F., Dignef, W., Ummelen, M., Sonke, G., Mravunac, M., Vooijs, G. P., Speel, E. M., & Ramaekers, F. C. (2004) · The Journal of Pathology · doi:10.1002/path.1490 · Cited by 173
Involvement of Human Papillomaviruses in Cervical Cancer
Wang, X., Huang, X., & Zhang, Y. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02896 · Cited by 173
Culp, T. D., Budgeon, L. R., Marinkovich, M. P., Meneguzzi, G., & Christensen, N. D. (2006) · Journal of Virology · doi:10.1128/jvi.00724-06 · Cited by 171
de Jong, A., O’Neill, T., Khan, A. Y., Kwappenberg, K. M. C., Chisholm, S. E., Whittle, N. R., Dobson, J. A., Jack, L. C., St Clair Roberts, J., Offringa, R., et al. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00350-x · Cited by 166
The biology of beta human papillomaviruses
Tommasino, M. (2016) · Virus Research · doi:10.1016/j.virusres.2016.11.013 · Cited by 166
Alcock, R., Cottingham, M. G., Rollier, C. S., Furze, J., De Costa, S. D., Hanlon, M., Spencer, A. J., Honeycutt, J. D., Wyllie, D. H., Gilbert, S. C., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000490 · Cited by 161
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection
Kemp, T. J., Hildesheim, A., Safaeian, M., Dauner, J. G., Pan, Y., Porras, C., Schiller, J. T., Lowy, D. R., Herrero, R., & Pinto, L. A. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.01.001 · Cited by 158
Holl, K., Nowakowski, A. M., Powell, N. G., McCluggage, W. G., Pirog, E. C., de Souza, S. C., Tjalma, W. A. A., Rosenlund, M., Fiander, A., Sánchez, M. C., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29651 · Cited by 156
Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia
Torres-Poveda, K. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.753 · Cited by 153
Lee, S. J., Yang, A. D., Wu, T. ‐., & Hung, C. (2016) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2016.27.e51 · Cited by 152
Pre-existing immunity against vaccine vectors – friend or foe?
Saxena, M., Van, T. T. H., Baird, F. J., Coloe, P. J., & Smooker, P. M. (2012) · Microbiology · doi:10.1099/mic.0.049601-0 · Cited by 151
Immunosuppressive Tumor Microenvironment in Cervical Cancer Patients
Piersma, S. J. (2011) · Cancer Microenvironment · doi:10.1007/s12307-011-0066-7 · Cited by 148
Day, P. M., Thompson, C. D., Schowalter, R. M., Lowy, D. R., & Schiller, J. T. (2013) · Journal of Virology · doi:10.1128/jvi.03222-12 · Cited by 148
Toll-like Receptor 9 Triggers an Innate Immune Response to Helper-dependent Adenoviral Vectors
Cerullo, V., Seiler, M. P., Mane, V. P., Brunetti‐Pierri, N., Clarke, C., Bertin, T., Rodgers, J. R., & Lee, B. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300031 · Cited by 143
Trimble, C. L., Clark, R. A., Thoburn, C. J., Hanson, N. C., Tassello, J., Frosina, D., Kos, F. J., Teague, J. E., Jiang, Y., Barat, N. C., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002756 · Cited by 140
Therapeutic vaccination against human papilloma virus induced malignancies
van der Burg, S. H., & Melief, C. J. M. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.12.010 · Cited by 139
Emerging viruses and current strategies for vaccine intervention
Afrough, B., Dowall, S., & Hewson, R. (2019) · Clinical & Experimental Immunology · doi:10.1111/cei.13295 · Cited by 128
Regression of Human Papillomavirus Intraepithelial Lesions Is Induced by MVA E2 Therapeutic Vaccine
Rosales, R., López‐Contreras, M., Rosales, C., Magallanes-Molina, J.-R., Gonzalez-Vergara, R., Arroyo-Cazarez, J. M., Ricardez-Arenas, A., del Follo-Valencia, A., Padilla-Arriaga, S., Guerrero, M. V., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.024 · Cited by 126
Human papillomaviruses and cancer
Haedicke, J., & Iftner, T. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.06.004 · Cited by 120
THE CARCINOGENIC EFFECT OF A PAPILLOMA VIRUS ON THE TARRED SKIN OF RABBITS
Rous, P., & Kidd, J. G. (1938) · The Journal of Experimental Medicine · doi:10.1084/jem.67.3.399 · Cited by 120
Immunogenicity Testing in Human Papillomavirus Virus‐Like‐Particle Vaccine Trials
Schiller, J. T., & Lowy, D. R. (2009) · The Journal of Infectious Diseases · doi:10.1086/599988 · Cited by 119
Wetherill, L. F., Holmes, K. K., Verow, M., Müller, M., Howell, G. J., Harris, M., Fishwick, C. W. G., Stonehouse, N. J., Foster, R., Blair, G. E., et al. (2012) · Journal of Virology · doi:10.1128/jvi.06243-11 · Cited by 119
Woo, Y. L., van den Hende, M., Sterling, J. C., Coleman, N., Crawford, R., Kwappenberg, K. M. C., Stanley, M., & van der Burg, S. H. (2009) · International Journal of Cancer · doi:10.1002/ijc.24804 · Cited by 117
Pinto, L. A., Dillner, J., Beddows, S. A., & Unger, E. R. (2018) · Vaccine · doi:10.1016/j.vaccine.2017.11.089 · Cited by 117
Kawana, K., Adachi, K., Kojima, S., Taguchi, A., Tomio, K., Yamashita, A., Nishida, H., Nagasaka, K., Arimoto, T., Yokoyama, T., et al. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.09.020 · Cited by 115
Varnavski, A. N., Young, P. R., & Khromykh, A. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.9.4394-4403.2000 · Cited by 113
hrHPV E5 oncoprotein: immune evasion and related immunotherapies
de Freitas, A. C., de Oliveira, T. H. A., Júnior, M. R. B., & Venuti, A. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0541-1 · Cited by 110
Long-term Study of a Quadrivalent Human Papillomavirus Vaccine
Ferris, D. G., Samakoses, R., Block, S. L., Lazcano-Ponce, E. C., Restrepo, J. A., Reisinger, K. S., Mehlsen, J., Chatterjee, A., Iversen, O., Sings, H. L., et al. (2014) · PEDIATRICS · doi:10.1542/peds.2013-4144 · Cited by 109
Garland, S. M., Paavonen, J. A., Jaisamrarn, U., Naud, P., Salmerón, J., Chow, S., Apter, D. L., Castellsagué, X., Teixeira, J. C., Skinner, S. R., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30391 · Cited by 104
Monnier‐Benoit, S., Mauny, F., Riethmuller, D., Guerrini, J.-S., Căpîlna, M. E., Felix, S. A., Seillès, E., Mougin, C., & Prétet, J. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.11.039 · Cited by 100
Vici, P., Pizzuti, L., Mariani, L., Zampa, G., Santini, D., Lauro, L. D., Gamucci, T., Natoli, C., Marchetti, P., Barba, M., et al. (2016) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1176533 · Cited by 100
Romanowski, B., Schwarz, T. F., Ferguson, L., Peters, K., Dionne, M., Behre, U., Schulze, K., Hillemanns, P., Suryakiran, P. V., Thomas, F., et al. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1065363 · Cited by 99
Replicon RNA Viral Vectors as Vaccines
Lundstrom, K. H. (2016) · Vaccines · doi:10.3390/vaccines4040039 · Cited by 92
Steele, J. C., Mann, C. H., Rookes, S. M., Rollason, T. P., Murphy, D., Freeth, M., Gallimore, P. H., & Roberts, S. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602679 · Cited by 91
Kivi, N., Greco, D., Auvinen, P., & Auvinen, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210916 · Cited by 89
Hartman, Z. C., Black, E. P., & Amalfitano, A. (2006) · Virology · doi:10.1016/j.virol.2006.08.041 · Cited by 87
Efficacy, duration of immunity and cross protection after HPV vaccination: A review of the evidence
Bonanni, P., Boccalini, S., & Bechini, A. (2009) · Vaccine · doi:10.1016/j.vaccine.2008.10.085 · Cited by 87
The role of furin in papillomavirus infection
Day, P. M., & Schiller, J. T. (2009) · Future Microbiology · doi:10.2217/fmb.09.86 · Cited by 84
Jit, M., Brisson, M., Laprise, J., & Choi, Y. H. (2015) · BMJ · doi:10.1136/bmj.g7584 · Cited by 83
RNA Viruses as Tools in Gene Therapy and Vaccine Development
Lundstrom, K. H. (2019) · Genes · doi:10.3390/genes10030189 · Cited by 82
Developments in L2-based human papillomavirus (HPV) vaccines
Schellenbacher, C., Roden, R. B. S., & Kirnbauer, R. (2016) · Virus Research · doi:10.1016/j.virusres.2016.11.020 · Cited by 81
Ramos, C. A., Narala, N., Vyas, G., Leen, A. M., Gerdemann, U., Sturgis, E. M., Anderson, M. L., Savoldo, B., Heslop, H. E., Brenner, M. K., et al. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318279652e · Cited by 78
Szarewski, A. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712591003601944 · Cited by 78
Towards quality and order in human papillomavirus research
Mühr, L. S. A., Eklund, C., & Dillner, J. (2018) · Virology · doi:10.1016/j.virol.2018.04.003 · Cited by 76
Cervical adenocarcinoma: Moving towards better prevention
Seoud, M. A.-F., Tjalma, W. A. A., & Ronsse, V. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.09.115 · Cited by 74
Tumban, E., Peabody, J., Peabody, D. S., & Chackerian, B. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.052 · Cited by 74
HPV vaccine cross-protection: Highlights on additional clinical benefit
Vincenzo, R. D., Ricci, C., Conte, C., & Scambia, G. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.05.033 · Cited by 74
Antigen‐specific immunotherapy of cervical and ovarian cancer
Hung, C., Wu, T. ‐., Monie, A., & Roden, R. B. S. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00622.x · Cited by 72
Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination
Coleman, H. N., Greenfield, W. W., Stratton, S. L., Vaughn, R., Kieber, A., Moerman, A., Spencer, H. J., Hitt, W. C., Quick, C. M., Hutchins, L. F., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1821-x · Cited by 72
Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells
Tsen, S., Paik, A. H., Hung, C., & Wu, T.-C. (2007) · Expert Review of Vaccines · doi:10.1586/14760584.6.2.227 · Cited by 70
Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata
Hawkins, M. G., Winder, D. M., Ball, S. L. R., Vaughan, K., Sonnex, C., Stanley, M., Sterling, J. C., & Goon, P. K. C. (2013) · Virology Journal · doi:10.1186/1743-422x-10-137 · Cited by 70
Self-Replicating RNA Viruses for RNA Therapeutics
Lundstrom, K. H. (2018) · Molecules · doi:10.3390/molecules23123310 · Cited by 70
Kim, J. H., Kang, T. H., Noh, K. H., Bae, H. C., Kim, S.-H., Yoo, Y. D., Seong, S., & Kim, T. W. (2009) · Immunology Letters · doi:10.1016/j.imlet.2008.12.006 · Cited by 68
Cruising the cellular highways: how human papillomavirus travels from the surface to the nucleus
DiGiuseppe, S., Bienkowska-Haba, M., Guion, L. G., & Sapp, M. (2017) · Virus Research · doi:10.1016/j.virusres.2016.10.015 · Cited by 67
Circumventing Antivector Immunity: Potential Use of Nonhuman Adenoviral Vectors
Lopez-Gordo, E., Podgorski, I. I., Downes, N., & Alemany, R. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.228 · Cited by 65
Morrow, M. P., Yan, J., & Sardesai, N. Y. (2013) · Expert Review of Vaccines · doi:10.1586/erv.13.23 · Cited by 65
Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer
Luckett, R. L., & Feldman, S. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1108500 · Cited by 63
HPV negative cervical cancers and primary HPV screening.
Tjalma, W. (2018) · PubMed Central · Cited by 61
Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery
Kim, S. J., Jung, K. H., Son, M. K., Park, J. H., YAN, H. H., Fang, Z., Kang, Y. W., Han, B., Lim, J. H., & Hong, S. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.06.035 · Cited by 60
Huber, B., Schellenbacher, C., Shafti‐Keramat, S., Jindra, C., Christensen, N. D., & Kirnbauer, R. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169533 · Cited by 55
Development of a highly thermostable, adjuvanted human papillomavirus vaccine
Hassett, K. J., Meinerz, N. M., Semmelmann, F., Cousins, M. C., Garcea, R. L., & Randolph, T. W. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.05.009 · Cited by 53
Carcinomatous Changes in Virus-induced Papillomas of the Skin of the Rabbit
Rous, P., & Beard, J. W. (1935) · Experimental Biology and Medicine · doi:10.3181/00379727-32-7770p · Cited by 52
Lm-LLO-Based Immunotherapies and HPV-Associated Disease
Wallecha, A., French, C. A., Petit, R. G., Singh, R., Amin, A. R., & Rothman, J. (2012) · Journal of Oncology · doi:10.1155/2012/542851 · Cited by 51
Kim, K. H., Greenfield, W. W., Cannon, M. J., Coleman, H. N., Spencer, H. J., & Nakagawa, M. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1092-5 · Cited by 51
Schwarz, T. F., Kocken, M., Petäjä, T., Einstein, M. H., Spaczyński, M., Louwers, J. A., Pedersen, C., Levin, M. J., Zahaf, T., Poncelet, S. M., et al. (2010) · Human Vaccines · doi:10.4161/hv.6.12.13399 · Cited by 51
Ahn, Y.-H., Hong, S.-O., Kim, J. H., Noh, K. H., Song, K.-H., Lee, Y.-H., Jeon, J.-H., Kim, D.-W., Seo, J., & Kim, T. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12620 · Cited by 50
Puthanakit, T., Huang, L., Chiu, C., Tang, R.-B., Schwarz, T. F., Esposito, S., Frenette, L., Giaquinto, C., McNeil, S., Rheault, P., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw036 · Cited by 50
Çuburu, N., Khan, S., Thompson, C. D., Kim, R., Vellinga, J., Zahn, R. C., Lowy, D. R., Scheper, G. C., & Schiller, J. T. (2017) · International Journal of Cancer · doi:10.1002/ijc.31166 · Cited by 50
Solares, A. M., Baladrón, I., Ramos, T. I., Valenzuela, C., Borbon, Z., Fanjull, S., Gonzalez, L., Castillo, D., Esmir, J., Granadillo, M., et al. (2011) · ISRN Obstetrics and Gynecology · doi:10.5402/2011/292951 · Cited by 47
Guevara, A., Cabello, R. L., Woelber, L. L., Moreira, E. D., Joura, E. A., Reich, O., Shields, C. E., Ellison, M. C., Joshi, A., & Luxembourg, A. T. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.07.017 · Cited by 43
Komatsu, A., Igimi, S., & Kawana, K. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.05.009 · Cited by 42
Qi, Z., Peng, S., Monie, A., Yang, M., Pang, X., Hung, C., & Wu, T. ‐. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.071 · Cited by 39
Wang, D., Li, Z., Xiao, J., Wang, J., Zhang, L., Liu, Y., Fan, F., Lü, X., Wei, M., Kong, Z., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123944 · Cited by 39
Paris, R., Bejrachandra, S., Thongcharoen, P., Nitayaphan, S., Pitisuttithum, P., Sambor, A., Gurunathan, S., Francis, D., Ratto-Kim, S., Karnasuta, C., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.11.002 · Cited by 37
Brancaccio, R. N., Robitaille, A., Dutta, S., Cuenin, C., Šantare, D., Šķenders, Ģ., Leja, M., Fischer, N., Giuliano, A. R., Rollison, D. E. M., et al. (2018) · Virology · doi:10.1016/j.virol.2018.04.017 · Cited by 37
Crosbie, E. J., & Kitchener, H. C. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.3.391 · Cited by 35
Incoming human papillomavirus 16 genome is lost in PML protein-deficient HaCaT keratinocytes
Bienkowska‐Haba, M., Łuszczek, W., Keiffer, T. R., Guion, L. G. M., DiGiuseppe, S., Scott, R. S., & Sapp, M. J. (2016) · Cellular Microbiology · doi:10.1111/cmi.12708 · Cited by 32
Ward, D., Thorsen, N. M., Frisch, M., Valentiner‐Branth, P., Mølbak, K., & Hviid, A. P. (2019) · Eurosurveillance · doi:10.2807/1560-7917.es.2019.24.19.1800380 · Cited by 31
Leung, T. F., Liu, A. P. Y., Lim, F. S., Thollot, F., Oh, H. M. L., Lee, B. W., Rombo, L., Tan, N. C., Rouzier, R., Simoni, S. D., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.11.034 · Cited by 30
Khan, S., Oosterhuis, K., Wunderlich, K., Bunnik, E. M., Bhaggoe, M., Boedhoe, S., Karia, S., Steenbergen, R. D. M., Bosch, L., Serroyen, J., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.30679 · Cited by 29
Kalnin, K. V., Chivukula, S. V., Tibbitts, T. J., Yan, Y., Stegalkina, S. S., Shen, L., Cieszynski, J., Costa, V., Sabharwal, R., Anderson, S. F., et al. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.07.086 · Cited by 29
Is HPV vaccination in pregnancy safe?
Bonde, U., Joergensen, J. S., Lamont, R., & Mogensen, O. E. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1160178 · Cited by 26
Myasthenia gravis following human papillomavirus vaccination: a case report
Chung, J. Y., Lee, S. J., Shin, B., & Kang, H. G. (2018) · BMC Neurology · doi:10.1186/s12883-018-1233-y · Cited by 25
Listeria monocytogenes and Its Products as Agents for Cancer Immunotherapy
Guirnalda, P. D., Wood, L. M., & Paterson, Y. Y. W. (2012) · Advances in immunology · doi:10.1016/b978-0-12-394590-7.00004-x · Cited by 24
Suragh, T. A., Lewis, P., Arana, J., Mba‐Jonas, A., Li, R., Stewart, B., Shimabukuro, T. T., & Cano, M. V. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13736 · Cited by 24
Neck and supraclavicular lymphadenopathy secondary to 9-valent human papillomavirus vaccination
Pereira, M. P., Flores, P., & Neto, A. S. (2019) · BMJ Case Reports · doi:10.1136/bcr-2019-231582 · Cited by 24
Chemoprevention of colorectal cancer: dietary and pharmacologic approaches.
Garay, C. A., & Engstrom, P. F. (1999) · PubMed · Cited by 23
Filling a gap in cervical cancer screening programmes
Wentzensen, N., & SCHIFFMAN, M. H. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70073-7 · Cited by 21
Effect of Different Human Papillomavirus Serological and DNA Criteria on Vaccine Efficacy Estimates
Kuhs, K. A. L., Porras, C., Schiller, J. T., Rodríguez, A. C., SCHIFFMAN, M. H., González, P., Wacholder, S., Ghosh, A., Li, Y., Lowy, D. R., et al. (2014) · American Journal of Epidemiology · doi:10.1093/aje/kwu168 · Cited by 21
Self-citationScavone, C., Mauro, C. D., Brusco, S., Bertini, M., di Mauro, G., Rafaniello, C., Sportiello, L., Rossi, F., & Capuano, A. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1598969 · Cited by 20
Jia, Y., Zhu, C., Du, J., Xiang, Y., Chen, Y., Wang, W., & Tao, C. (2019) · PeerJ · doi:10.7717/peerj.7490 · Cited by 6
Cited by
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · Cancer Communications · doi:10.1002/cac2.12539 · Cited by 364
Virus-like particle vaccinology, from bench to bedside
Mohsen, M. O., & Bachmann, M. F. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00897-8 · Cited by 289
Metadata
- Authors
- Wang, R., Pan, W., Jin, L., Huang, W., Li, Y., Wu, D., Gao, C., Ma, D., & Liao, S.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 471
- Pages
- 88-102
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2992033969
- Cited by
- 493
- References
- 179
- FWCI
- 30.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.